Effect of the Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes

Bruce B Redmon, Alain G. Bertoni, Stephanie Connelly, Patricia A. Feeney, Stephen P. Glasser, Henry Glick, Frank Greenway, Louise A. Hesson, Michael S. Lawlor, Maria Montez, Brenda Montgomery

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

OBJECTIVE - To examine the effect of a lifestyle intervention to produce weight loss and increased physical fitness on use and cost of medications to treat cardiovascular disease (CVD) risk factors in people with type 2 diabetes. RESEARCH DESIGN AND METHODS - Look AHEAD is a multicenter randomized controlled trial of 5,145 overweight or obese individuals with type 2 diabetes, aged 45-76 years. An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared with a diabetes support and education (DSE) condition. Medications prescribed to treat diabetes, hypertension, and hyperlipidemia were compared at baseline and 1 year. Medication costs were conservatively estimated using prices from a national online pharmacy. RESULTS - Participants randomized to an ILI had significantly greater improvements in CVD risk parameters and reduced medication use and cost compared with those assigned to DSE. At 1 year, average number of medications prescribed to treat CVD risk factors was 3.1 ± 1.8 for the ILI group and 3.6 ± 1.8 for the DSE group (P < 0.0001), with estimated total monthly medication costs of $143 and $173, respectively (P < 0.0001). DSE participants meeting optimal care goals at 1 year were taking an average of 3.8 ± 1.6 medications at an estimated cost of $194/month. ILI participants at optimal care required fewer medications (3.2 ± 1.7) at lower cost ($154/month) (P < 0.001). CONCLUSIONS - At 1 year, ILI significantly improved CVD risk factors, while at the same time reduced medication use and cost. Continued intervention and follow-up will determine whether these changes are maintained and reduce cardiovascular risk.

Original languageEnglish (US)
Pages (from-to)1153-1158
Number of pages6
JournalDiabetes care
Volume33
Issue number6
DOIs
StatePublished - Jun 1 2010

Fingerprint

Type 2 Diabetes Mellitus
Cardiovascular Diseases
Life Style
Costs and Cost Analysis
Education
Online Pharmaceutical Services
Weight Loss
Group Processes
Physical Fitness
Hyperlipidemias
Energy Intake
Research Design
Randomized Controlled Trials
Hypertension

Cite this

Effect of the Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. / Redmon, Bruce B; Bertoni, Alain G.; Connelly, Stephanie; Feeney, Patricia A.; Glasser, Stephen P.; Glick, Henry; Greenway, Frank; Hesson, Louise A.; Lawlor, Michael S.; Montez, Maria; Montgomery, Brenda.

In: Diabetes care, Vol. 33, No. 6, 01.06.2010, p. 1153-1158.

Research output: Contribution to journalArticle

Redmon, BB, Bertoni, AG, Connelly, S, Feeney, PA, Glasser, SP, Glick, H, Greenway, F, Hesson, LA, Lawlor, MS, Montez, M & Montgomery, B 2010, 'Effect of the Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes', Diabetes care, vol. 33, no. 6, pp. 1153-1158. https://doi.org/10.2337/dc09-2090
Redmon, Bruce B ; Bertoni, Alain G. ; Connelly, Stephanie ; Feeney, Patricia A. ; Glasser, Stephen P. ; Glick, Henry ; Greenway, Frank ; Hesson, Louise A. ; Lawlor, Michael S. ; Montez, Maria ; Montgomery, Brenda. / Effect of the Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. In: Diabetes care. 2010 ; Vol. 33, No. 6. pp. 1153-1158.
@article{5c3d228b672a44fa9cc1ac258f0ee8e0,
title = "Effect of the Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes",
abstract = "OBJECTIVE - To examine the effect of a lifestyle intervention to produce weight loss and increased physical fitness on use and cost of medications to treat cardiovascular disease (CVD) risk factors in people with type 2 diabetes. RESEARCH DESIGN AND METHODS - Look AHEAD is a multicenter randomized controlled trial of 5,145 overweight or obese individuals with type 2 diabetes, aged 45-76 years. An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared with a diabetes support and education (DSE) condition. Medications prescribed to treat diabetes, hypertension, and hyperlipidemia were compared at baseline and 1 year. Medication costs were conservatively estimated using prices from a national online pharmacy. RESULTS - Participants randomized to an ILI had significantly greater improvements in CVD risk parameters and reduced medication use and cost compared with those assigned to DSE. At 1 year, average number of medications prescribed to treat CVD risk factors was 3.1 ± 1.8 for the ILI group and 3.6 ± 1.8 for the DSE group (P < 0.0001), with estimated total monthly medication costs of $143 and $173, respectively (P < 0.0001). DSE participants meeting optimal care goals at 1 year were taking an average of 3.8 ± 1.6 medications at an estimated cost of $194/month. ILI participants at optimal care required fewer medications (3.2 ± 1.7) at lower cost ($154/month) (P < 0.001). CONCLUSIONS - At 1 year, ILI significantly improved CVD risk factors, while at the same time reduced medication use and cost. Continued intervention and follow-up will determine whether these changes are maintained and reduce cardiovascular risk.",
author = "Redmon, {Bruce B} and Bertoni, {Alain G.} and Stephanie Connelly and Feeney, {Patricia A.} and Glasser, {Stephen P.} and Henry Glick and Frank Greenway and Hesson, {Louise A.} and Lawlor, {Michael S.} and Maria Montez and Brenda Montgomery",
year = "2010",
month = "6",
day = "1",
doi = "10.2337/dc09-2090",
language = "English (US)",
volume = "33",
pages = "1153--1158",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - Effect of the Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes

AU - Redmon, Bruce B

AU - Bertoni, Alain G.

AU - Connelly, Stephanie

AU - Feeney, Patricia A.

AU - Glasser, Stephen P.

AU - Glick, Henry

AU - Greenway, Frank

AU - Hesson, Louise A.

AU - Lawlor, Michael S.

AU - Montez, Maria

AU - Montgomery, Brenda

PY - 2010/6/1

Y1 - 2010/6/1

N2 - OBJECTIVE - To examine the effect of a lifestyle intervention to produce weight loss and increased physical fitness on use and cost of medications to treat cardiovascular disease (CVD) risk factors in people with type 2 diabetes. RESEARCH DESIGN AND METHODS - Look AHEAD is a multicenter randomized controlled trial of 5,145 overweight or obese individuals with type 2 diabetes, aged 45-76 years. An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared with a diabetes support and education (DSE) condition. Medications prescribed to treat diabetes, hypertension, and hyperlipidemia were compared at baseline and 1 year. Medication costs were conservatively estimated using prices from a national online pharmacy. RESULTS - Participants randomized to an ILI had significantly greater improvements in CVD risk parameters and reduced medication use and cost compared with those assigned to DSE. At 1 year, average number of medications prescribed to treat CVD risk factors was 3.1 ± 1.8 for the ILI group and 3.6 ± 1.8 for the DSE group (P < 0.0001), with estimated total monthly medication costs of $143 and $173, respectively (P < 0.0001). DSE participants meeting optimal care goals at 1 year were taking an average of 3.8 ± 1.6 medications at an estimated cost of $194/month. ILI participants at optimal care required fewer medications (3.2 ± 1.7) at lower cost ($154/month) (P < 0.001). CONCLUSIONS - At 1 year, ILI significantly improved CVD risk factors, while at the same time reduced medication use and cost. Continued intervention and follow-up will determine whether these changes are maintained and reduce cardiovascular risk.

AB - OBJECTIVE - To examine the effect of a lifestyle intervention to produce weight loss and increased physical fitness on use and cost of medications to treat cardiovascular disease (CVD) risk factors in people with type 2 diabetes. RESEARCH DESIGN AND METHODS - Look AHEAD is a multicenter randomized controlled trial of 5,145 overweight or obese individuals with type 2 diabetes, aged 45-76 years. An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared with a diabetes support and education (DSE) condition. Medications prescribed to treat diabetes, hypertension, and hyperlipidemia were compared at baseline and 1 year. Medication costs were conservatively estimated using prices from a national online pharmacy. RESULTS - Participants randomized to an ILI had significantly greater improvements in CVD risk parameters and reduced medication use and cost compared with those assigned to DSE. At 1 year, average number of medications prescribed to treat CVD risk factors was 3.1 ± 1.8 for the ILI group and 3.6 ± 1.8 for the DSE group (P < 0.0001), with estimated total monthly medication costs of $143 and $173, respectively (P < 0.0001). DSE participants meeting optimal care goals at 1 year were taking an average of 3.8 ± 1.6 medications at an estimated cost of $194/month. ILI participants at optimal care required fewer medications (3.2 ± 1.7) at lower cost ($154/month) (P < 0.001). CONCLUSIONS - At 1 year, ILI significantly improved CVD risk factors, while at the same time reduced medication use and cost. Continued intervention and follow-up will determine whether these changes are maintained and reduce cardiovascular risk.

UR - http://www.scopus.com/inward/record.url?scp=77956071596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956071596&partnerID=8YFLogxK

U2 - 10.2337/dc09-2090

DO - 10.2337/dc09-2090

M3 - Article

VL - 33

SP - 1153

EP - 1158

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -